
Rubedo Life Sciences, a biopharmaceutical firm, innovates therapies targeting age-related diseases using its ALEMBIC platform.
Rubedo Life Sciences, founded with a mission to combat chronic age-related diseases, leverages its proprietary ALEMBIC drug discovery platform to develop innovative therapies. The company focuses on creating first-in-class small molecules that selectively target senescent cells, which contribute to conditions such as pulmonary, dermatological, oncological, neurodegenerative, and fibrotic diseases. Rubedo aims to transform the treatment landscape for these chronic conditions through its cutting-edge biopharmaceutical solutions.
Notable investors in Rubedo Life Sciences include Khosla Ventures and Ahren Innovation Capital, who led a $40 million Series A financing round. The company has also formed a significant partnership with Beiersdorf to develop new skincare products addressing cellular aging. Among its key achievements is the nomination of its first-in-class disease-modifying candidate RLS- in dermatology. Rubedo's innovative approach and strategic collaborations have positioned it as a promising player in the biopharmaceutical industry, making substantial strides in targeting age-related diseases.

Rejuveron Life Sciences
rejuveron.com

Retro Biosciences
retro.bio

Gerostate Alpha

Regenerative Bio
regen-bio.us

BioAge Labs
bioagelabs.com

Cambrian BioPharma
cambrianbio.com

Spring Discovery

Rediscovery Life Sciences
rediscoveryls.com

Longeveron
longeveron.com

AgeX Therapeutics

EdenRoc Sciences

Deciduous Therapeutics
deciduoustx.com

Alveolus Bio
alveolusbio.com

Juvenescence
juvlabs.com

Oisin Biotechnologies
oisinbio.com
Companies similar to Rubedo Life Sciences include Rejuveron Life Sciences, Retro Biosciences, Gerostate Alpha and Regenerative Bio.
Rubedo Life Sciences was founded in 2018.
Rubedo Life Sciences' headquarters is located in Sunnyvale, CA, US.
As of Oct 31, 2023, Rubedo Life Sciences has raised a total of $13.4M (USD).
Rubedo Life Sciences has 28 employees as of Feb 4, 2024.